Bayer has agreed to acquire San Francisco-based biotech startup Perfuse Therapeutics in a deal potentially worth $2.45 billion. This marks... Read more
Bayer to acquire Perfuse for up to $2.45B to bolster its ophthalmology pipeline
07/05/2026
Published by ViNe
